Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Clinical trial NCT06960577 · RECRUITING

Trial details

NCT number: NCT06960577
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Urinary Bladder Neoplasms Immune Checkpoint Inhibitors Methotrexate Vinblastine Doxorubicin Cisplatin Gemcitabine

Start date: 2025-05-15
Primary completion: 2028-10-31
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.